{"id":68674,"date":"2026-06-22T20:16:33","date_gmt":"2026-06-22T12:16:33","guid":{"rendered":"https:\/\/flcube.com\/?p=68674"},"modified":"2026-06-22T20:16:34","modified_gmt":"2026-06-22T12:16:34","slug":"dawnrays-pharmaceutical-launches-rmb-200-million-biopharma-venture-fund-with-shanghai-jianxin-partners","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68674","title":{"rendered":"Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Dawnrays Pharmaceutical (Holdings) Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2348:HKG\">HKG: 2348<\/a>) announced the formation of the <strong>Shanghai Jianxin Dawnrays Biopharmaceutical Venture Capital Investment Fund Partnership<\/strong>, a strategic collaboration with <strong>Zhongjianxin Holdings<\/strong> and <strong>Shanghai Jianxin Chuangke Equity Investment Management<\/strong>. The fund will have <strong>total committed capital of RMB 200 million<\/strong> (approximately <strong>USD 29.5 million<\/strong>) and focus exclusively on investments in <strong>pharmaceutical, biotechnology, and healthcare sectors<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-fund-structure-amp-financial-commitments\" class=\"wp-block-heading\">Fund Structure &amp; Financial Commitments<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Fund Size<\/strong><\/td><td>RMB 200 million (USD 29.5 million)<\/td><\/tr><tr><td><strong>Dawnrays Commitment<\/strong><\/td><td>RMB 100 million (USD 14.75 million)<\/td><\/tr><tr><td><strong>Dawnrays Ownership<\/strong><\/td><td>50% of total partnership capital<\/td><\/tr><tr><td><strong>Co-Investors<\/strong><\/td><td>Zhongjianxin Holdings, Shanghai Jianxin Chuangke Equity Investment Management<\/td><\/tr><tr><td><strong>Investment Focus<\/strong><\/td><td>Pharmaceutical, biotechnology, and healthcare sectors<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>Primarily China-focused with potential international opportunities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-investment-strategy\" class=\"wp-block-heading\">Strategic Rationale &amp; Investment Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sector Specialization:<\/strong> Dedicated focus on high-growth <strong>biopharmaceutical innovation<\/strong>, leveraging Dawnrays&#8217; industry expertise and network<\/li>\n\n\n\n<li><strong>Early-Stage Emphasis:<\/strong> Target investments in <strong>preclinical to Phase II assets<\/strong>, providing capital and strategic guidance to emerging biotech companies<\/li>\n\n\n\n<li><strong>Vertical Integration:<\/strong> Potential to create synergies with Dawnrays&#8217; existing pharmaceutical operations through licensing, partnerships, or acquisition opportunities<\/li>\n\n\n\n<li><strong>Risk Diversification:<\/strong> Portfolio approach across multiple therapeutic areas and development stages to balance risk-return profile<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chinese Biotech Funding Gap:<\/strong> Despite robust innovation, Chinese biotech startups face increasing challenges securing Series A-B funding amid global venture capital contraction<\/li>\n\n\n\n<li><strong>Strategic Corporate VC Trend:<\/strong> Major Chinese pharmaceutical companies are increasingly establishing dedicated investment vehicles to access external innovation and maintain competitive pipelines<\/li>\n\n\n\n<li><strong>Shanghai Biotech Hub:<\/strong> The fund leverages Shanghai&#8217;s position as China&#8217;s leading biopharmaceutical cluster, with proximity to research institutions, regulatory agencies, and talent pools<\/li>\n\n\n\n<li><strong>Government Support:<\/strong> Aligns with China&#8217;s national strategy to develop domestic biopharmaceutical capabilities and reduce reliance on imported medicines<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-amp-strategic-implications\" class=\"wp-block-heading\">Financial &amp; Strategic Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Dawnrays&#8217; <strong>50% capital commitment<\/strong> demonstrates significant strategic investment in the broader biopharmaceutical ecosystem beyond its core operations. The venture fund structure provides Dawnrays with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Optionality:<\/strong> Early access to promising therapeutic candidates and technologies<\/li>\n\n\n\n<li><strong>Innovation Scouting:<\/strong> Systematic evaluation of emerging scientific platforms and business models<\/li>\n\n\n\n<li><strong>Return Potential:<\/strong> Financial upside from successful portfolio exits while supporting sector development<\/li>\n\n\n\n<li><strong>Ecosystem Building:<\/strong> Strengthened relationships with academic institutions, startups, and other strategic partners<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts view this move as part of Dawnrays&#8217; broader transformation from traditional pharmaceutical manufacturer to integrated healthcare innovator, following similar strategies adopted by larger Chinese peers like CSPC and Hengrui Medicine.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding fund establishment, investment strategies, and strategic objectives. Actual results may differ due to regulatory approvals, market conditions, and investment performance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061802113_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061802113_c.\"><\/object><a id=\"wp-block-file--media-4fc6c4ae-324f-4c76-bb86-be8e32047172\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061802113_c.pdf\">2026061802113_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061802113_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4fc6c4ae-324f-4c76-bb86-be8e32047172\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dawnrays Pharmaceutical (Holdings) Limited (HKG: 2348) announced the formation of the Shanghai Jianxin Dawnrays Biopharmaceutical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1526,1525],"class_list":["post-68674","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-dawnrays-pharmaceutical","tag-hkg-2348"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Dawnrays Pharmaceutical (Holdings) Limited (HKG: 2348) announced the formation of the Shanghai Jianxin Dawnrays Biopharmaceutical Venture Capital Investment Fund Partnership, a strategic collaboration with Zhongjianxin Holdings and Shanghai Jianxin Chuangke Equity Investment Management. The fund will have total committed capital of RMB 200 million (approximately USD 29.5 million) and focus exclusively on investments in pharmaceutical, biotechnology, and healthcare sectors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68674\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners\" \/>\n<meta property=\"og:description\" content=\"Dawnrays Pharmaceutical (Holdings) Limited (HKG: 2348) announced the formation of the Shanghai Jianxin Dawnrays Biopharmaceutical Venture Capital Investment Fund Partnership, a strategic collaboration with Zhongjianxin Holdings and Shanghai Jianxin Chuangke Equity Investment Management. The fund will have total committed capital of RMB 200 million (approximately USD 29.5 million) and focus exclusively on investments in pharmaceutical, biotechnology, and healthcare sectors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68674\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-22T12:16:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-22T12:16:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68674#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68674\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners\",\"datePublished\":\"2026-06-22T12:16:33+00:00\",\"dateModified\":\"2026-06-22T12:16:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68674\"},\"wordCount\":419,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Dawnrays Pharmaceutical\",\"HKG: 2348\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68674#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68674\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68674\",\"name\":\"Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-22T12:16:33+00:00\",\"dateModified\":\"2026-06-22T12:16:34+00:00\",\"description\":\"Dawnrays Pharmaceutical (Holdings) Limited (HKG: 2348) announced the formation of the Shanghai Jianxin Dawnrays Biopharmaceutical Venture Capital Investment Fund Partnership, a strategic collaboration with Zhongjianxin Holdings and Shanghai Jianxin Chuangke Equity Investment Management. The fund will have total committed capital of RMB 200 million (approximately USD 29.5 million) and focus exclusively on investments in pharmaceutical, biotechnology, and healthcare sectors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68674#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68674\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68674#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners - Insight, China&#039;s Pharmaceutical Industry","description":"Dawnrays Pharmaceutical (Holdings) Limited (HKG: 2348) announced the formation of the Shanghai Jianxin Dawnrays Biopharmaceutical Venture Capital Investment Fund Partnership, a strategic collaboration with Zhongjianxin Holdings and Shanghai Jianxin Chuangke Equity Investment Management. The fund will have total committed capital of RMB 200 million (approximately USD 29.5 million) and focus exclusively on investments in pharmaceutical, biotechnology, and healthcare sectors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68674","og_locale":"en_US","og_type":"article","og_title":"Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners","og_description":"Dawnrays Pharmaceutical (Holdings) Limited (HKG: 2348) announced the formation of the Shanghai Jianxin Dawnrays Biopharmaceutical Venture Capital Investment Fund Partnership, a strategic collaboration with Zhongjianxin Holdings and Shanghai Jianxin Chuangke Equity Investment Management. The fund will have total committed capital of RMB 200 million (approximately USD 29.5 million) and focus exclusively on investments in pharmaceutical, biotechnology, and healthcare sectors.","og_url":"https:\/\/flcube.com\/?p=68674","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-22T12:16:33+00:00","article_modified_time":"2026-06-22T12:16:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68674#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68674"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners","datePublished":"2026-06-22T12:16:33+00:00","dateModified":"2026-06-22T12:16:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68674"},"wordCount":419,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Dawnrays Pharmaceutical","HKG: 2348"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68674#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68674","url":"https:\/\/flcube.com\/?p=68674","name":"Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-22T12:16:33+00:00","dateModified":"2026-06-22T12:16:34+00:00","description":"Dawnrays Pharmaceutical (Holdings) Limited (HKG: 2348) announced the formation of the Shanghai Jianxin Dawnrays Biopharmaceutical Venture Capital Investment Fund Partnership, a strategic collaboration with Zhongjianxin Holdings and Shanghai Jianxin Chuangke Equity Investment Management. The fund will have total committed capital of RMB 200 million (approximately USD 29.5 million) and focus exclusively on investments in pharmaceutical, biotechnology, and healthcare sectors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68674#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68674"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68674#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68674"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68674\/revisions"}],"predecessor-version":[{"id":68677,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68674\/revisions\/68677"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}